Thymoglobulin isn't a Renagel replay

When one company buys another company with a marketed product, it's frequently safe to conclude that the purchase is being done for that product alone - no matter what the purchaser says about synergies, pipelines or strategic fit. But then there are the exceptions.
Genzyme Corp. says last week's deal to acquire SangStat Medical Corp. for $600 million in cash is not being done for SANG's marketed Thymoglobulin transplant product, although GENZ does believe that it can ramp sales faster than SANG could. Instead, the purchase is part

Read the full 878 word article

User Sign In

Article Purchase

This article may not be distributed to non-subscribers

PURCHASE THIS ARTICLE FOR LIMITED ONE-TIME DISTRIBUTION AND WEBSITE POSTING $995.00 USD

PURCHASE